LT4476B - Peptidas ir jo gavimo būdas - Google Patents

Peptidas ir jo gavimo būdas Download PDF

Info

Publication number: LT4476B
Authority: LT; Lithuania
Prior art keywords: trp; glu; ala; phe; leu
Prior art date: 1995-06-07

Application number

LT98-004A

Other languages

English (en)

Lithuanian (lt)

Other versions

LT98004A (en

Inventor

Vladislav Isakovich Deigin

Andrei Marxovich Korotkov

Original Assignee

Vladislav Isakovich Deigin

Andrei Marxovich Korotkov

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-06-07

Filing date

1998-01-07

Publication date

1999-03-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20168146&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT4476(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1998-01-07 Application filed by Vladislav Isakovich Deigin, Andrei Marxovich Korotkov filed Critical Vladislav Isakovich Deigin

1998-10-26 Publication of LT98004A publication Critical patent/LT98004A/xx

1999-03-25 Publication of LT4476B publication Critical patent/LT4476B/lt

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 28
238000000034 method Methods 0.000 title abstract description 8
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims abstract description 16
ONIBWKKTOPOVIA-SCSAIBSYSA-N D-Proline Chemical compound OC(=O)[C@H]1CCCN1 ONIBWKKTOPOVIA-SCSAIBSYSA-N 0.000 claims abstract description 8
QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims abstract description 8
ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 claims abstract description 8
QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 claims abstract description 8
SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 claims abstract description 8
SLXKOJJOQWFEFD-UHFFFAOYSA-M 6-aminohexanoate Chemical compound NCCCCCC([O-])=O SLXKOJJOQWFEFD-UHFFFAOYSA-M 0.000 claims abstract description 7
COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 claims abstract description 7
KZSNJWFQEVHDMF-SCSAIBSYSA-N D-valine Chemical compound CC(C)[C@@H](N)C(O)=O KZSNJWFQEVHDMF-SCSAIBSYSA-N 0.000 claims abstract description 7
OUYCCCASQSFEME-MRVPVSSYSA-N D-tyrosine Chemical compound OC(=O)[C@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-MRVPVSSYSA-N 0.000 claims abstract description 6
238000003786 synthesis reaction Methods 0.000 claims abstract description 6
239000002253 acid Substances 0.000 claims abstract description 4
150000001408 amides Chemical class 0.000 claims abstract description 4
230000007017 scission Effects 0.000 claims abstract description 4
150000002148 esters Chemical class 0.000 claims abstract description 3
AGPKZVBTJJNPAG-RFZPGFLSSA-N D-Isoleucine Chemical compound CC[C@@H](C)[C@@H](N)C(O)=O AGPKZVBTJJNPAG-RFZPGFLSSA-N 0.000 claims abstract 4
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims abstract 4
125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 claims abstract 4
125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 claims abstract 4
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims abstract 4
150000008064 anhydrides Chemical class 0.000 claims abstract 3
-1 D-NVal Chemical compound 0.000 claims description 6
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 4
238000003776 cleavage reaction Methods 0.000 claims description 3
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 2
235000019253 formic acid Nutrition 0.000 claims description 2
239000003814 drug Substances 0.000 abstract description 7
102000004196 processed proteins & peptides Human genes 0.000 abstract description 6
230000015572 biosynthetic process Effects 0.000 abstract description 5
230000004957 immunoregulator effect Effects 0.000 abstract description 5
239000013543 active substance Substances 0.000 abstract description 3
238000013375 chromatographic separation Methods 0.000 abstract description 2
OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 abstract 2
229960003692 gamma aminobutyric acid Drugs 0.000 abstract 2
WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 abstract 1
150000001413 amino acids Chemical class 0.000 abstract 1
238000010504 bond cleavage reaction Methods 0.000 abstract 1
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
239000000243 solution Substances 0.000 description 9
239000000203 mixture Substances 0.000 description 7
238000002360 preparation method Methods 0.000 description 7
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
AQTUACKQXJNHFQ-ZCFIWIBFSA-N (2r)-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanedioic acid Chemical compound CC(C)(C)OC(=O)N[C@@H](C(O)=O)CCC(O)=O AQTUACKQXJNHFQ-ZCFIWIBFSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
239000000284 extract Substances 0.000 description 3
210000004989 spleen cell Anatomy 0.000 description 3
239000000126 substance Substances 0.000 description 3
ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
208000037581 Persistent Infection Diseases 0.000 description 2
241000246358 Thymus Species 0.000 description 2
235000007303 Thymus vulgaris Nutrition 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
230000004663 cell proliferation Effects 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
238000011161 development Methods 0.000 description 2
230000000694 effects Effects 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000000463 material Substances 0.000 description 2
239000002609 medium Substances 0.000 description 2
239000012044 organic layer Substances 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
238000003756 stirring Methods 0.000 description 2
239000001585 thymus vulgaris Substances 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
108010062580 Concanavalin A Proteins 0.000 description 1
229930105110 Cyclosporin A Natural products 0.000 description 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
108010036949 Cyclosporine Proteins 0.000 description 1
125000003625 D-valyl group Chemical group N[C@@H](C(=O)*)C(C)C 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
208000029462 Immunodeficiency disease Diseases 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
206010040047 Sepsis Diseases 0.000 description 1
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
102000007501 Thymosin Human genes 0.000 description 1
108010046075 Thymosin Proteins 0.000 description 1
239000008351 acetate buffer Substances 0.000 description 1
MTEUMURLJRZUKD-UHFFFAOYSA-N acetic acid;butan-1-ol;pyridine;hydrate Chemical compound O.CC(O)=O.CCCCO.C1=CC=NC=C1 MTEUMURLJRZUKD-UHFFFAOYSA-N 0.000 description 1
150000008065 acid anhydrides Chemical class 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000007059 acute toxicity Effects 0.000 description 1
231100000403 acute toxicity Toxicity 0.000 description 1
229960002684 aminocaproic acid Drugs 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
229960001265 ciclosporin Drugs 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000001816 cooling Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
230000007813 immunodeficiency Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
239000003226 mitogen Substances 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
210000004303 peritoneum Anatomy 0.000 description 1
239000002831 pharmacologic agent Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000000047 product Substances 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
GAPYKZAARZMMGP-UHFFFAOYSA-N pyridin-1-ium;acetate Chemical compound CC(O)=O.C1=CC=NC=C1 GAPYKZAARZMMGP-UHFFFAOYSA-N 0.000 description 1
238000000926 separation method Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
238000012360 testing method Methods 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
238000002211 ultraviolet spectrum Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0819—Tripeptides with the first amino acid being acidic
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
- C07K5/0823—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp and Pro-amino acid; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

LT98-004A 1995-06-07 1998-01-07 Peptidas ir jo gavimo būdas LT4476B (lt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
RU95108559A RU2107692C1 (ru)	1995-06-07	1995-06-07	Пептид и способ его получения

Publications (2)

Publication Number	Publication Date
LT98004A LT98004A (en)	1998-10-26
LT4476B true LT4476B (lt)	1999-03-25

Family

ID=20168146

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LT98-004A LT4476B (lt)	1995-06-07	1998-01-07	Peptidas ir jo gavimo būdas

Country Status (20)

Country	Link
US (1)	US5736519A (da)
EP (1)	EP0832900B1 (da)
JP (1)	JP4082522B2 (da)
CN (1)	CN1154653C (da)
AT (1)	ATE260933T1 (da)
AU (1)	AU724781B2 (da)
BR (1)	BRPI9609235B8 (da)
CA (1)	CA2222296C (da)
CZ (1)	CZ287816B6 (da)
DE (1)	DE69631762T2 (da)
DK (1)	DK0832900T3 (da)
ES (1)	ES2217311T3 (da)
HU (1)	HU228461B1 (da)
LT (1)	LT4476B (da)
LV (1)	LV12074B (da)
PT (1)	PT832900E (da)
RU (1)	RU2107692C1 (da)
SK (1)	SK281825B6 (da)
UA (1)	UA48974C2 (da)
WO (1)	WO1996040740A1 (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2107691C1 (ru) *	1995-03-02	1998-03-27	Дейгин Владислав Исакович	Пептид и способ его получения
US5916878A (en) *	1995-11-28	1999-06-29	Edward T. Wei	γ-glutamyl and β-aspartyl containing immunomodulator compounds and methods therewith
US6159940A (en) *	1996-02-28	2000-12-12	Immunotech Developments Inc.	Method for modulating hemopoiesis
DE19712633A1 (de) *	1997-03-26	1998-10-08	Laves Arzneimittel	Verwendung von gamma-Aminobuttersäure als Interleukinbildungsstimulans
IL145926A0 (en)	2001-10-15	2002-07-25	Mor Research Applic Ltd	Peptide epitopes of mimotopes useful in immunomodulation
IL155136A0 (en)	2003-02-10	2003-10-31	Enzymotec Ltd	A composition for reducing blood cholesterol and triglycerides
US20060233863A1 (en)	2003-02-10	2006-10-19	Enzymotec Ltd.	Oils enriched with diacylglycerols and phytosterol esters and unit dosage forms thereof for use in therapy
JP4629033B2 (ja)	2003-03-28	2011-02-09	サイクローン・ファーマシューティカルズ・インコーポレイテッド	チモシンα１によるアスペルギルス感染の治療
US20090232916A1 (en) *	2004-08-09	2009-09-17	Avidor Shulman	Food products for diabetics
AU2005270831B2 (en)	2004-08-10	2011-08-25	Enzymotec Ltd.	Mixture of phytosterol ester(s) and 1, 3-diglyceride(s) for use in the treatment of medical conditions
WO2006131833A2 (en) *	2005-03-18	2006-12-14	Centre National De La Recherche Scientifique	New hybrid oligomers. their preparation process and pharmaceutical compositions containing them
US7919468B2 (en)	2005-04-07	2011-04-05	Centre National De La Recherche Scientifique (C.N.R.S.)	Compounds useful as modulators of the proteasome activity
WO2007000768A2 (en) *	2005-06-28	2007-01-04	Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science	Gliomedin, fragments thereof and methods of using same
RU2320364C1 (ru) *	2006-08-21	2008-03-27	Закрытое Акционерное Общество "Центр "Пептос"	Способ лечения злокачественных новообразований
CA2569204A1 (en)	2006-11-28	2008-05-28	Apotex Technologies Inc.	Crystalline d-isoglutamyl-d-tryptophan and the mono ammonium salt of d-isoglutamyl-d-tryptophan
CA2571645A1 (en)	2006-12-19	2008-06-19	Apotex Technologies Inc.	Pharmaceutically acceptable salts of thymodepressin and processes for their manufacture
MX2009008641A (es)	2007-02-13	2009-09-14	Sciclone Pharmaceuticals Inc	Composiciones para el tratamiento o prevencion del deterioro, lesion o daño a tejido debido a enfermedad de las mucosas.
CA2579119C (en)	2007-02-16	2013-03-05	Apotex Technologies Inc.	Crystalline forms of the mono-sodium salt of d-isoglutamyl-d-tryptophan
WO2008142693A2 (en) *	2007-05-22	2008-11-27	Yeda Research And Development Co. Ltd.	Regulation of myelination by nectin-like (necl) molecules
RU2410391C1 (ru) *	2009-06-03	2011-01-27	Общество с ограниченной ответственностью "Пептос Фарма"	Пептиды, влияющие на регенерацию кроветворной системы, и фармацевтическая композиция на их основе
EA201391419A1 (ru) *	2011-03-31	2014-02-28	Апотекс Текнолоджиз Инк.	Пролекарства d-изоглутамил-[d/l]-триптофана
CA2831429A1 (en) *	2011-03-31	2012-10-04	Apotex Technologies Inc.	Prodrugs of d-gamma-glutamyl-d-tryptophan and d-gamma- glutamyl-l-tryptophan
CN102417474B (zh) *	2011-09-26	2014-07-02	深圳翰宇药业股份有限公司	D-异谷氨酰基-d-色氨酸制备的新方法
RU2634258C1 (ru) *	2016-11-08	2017-10-24	федеральное государственное автономное образовательное учреждение высшего образования "Российский университет дружбы народов" (РУДН)	Наполнитель для капсульного ингалятора

Citations (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH659586A5 (de)	1985-07-02	1987-02-13	Le G Ped I	Arzneimittel aus dem thymus und verfahren zu dessen herstellung.
EP0230052A2 (en)	1985-12-26	1987-07-29	Arthur A. Gottlieb	Immunoamplifiers and related Compositions
WO1989006134A1 (fr)	1987-12-30	1989-07-13	Vsesojuzny Kardiologichesky Nauchny Tsentr Akademi	Preparation pharmaceutique pour traiter des etats immunodeficitaires
EP0406931A2 (en)	1989-06-30	1991-01-09	SCLAVO S.p.A.	New analogues of all-bond retroinverted thymopentin, the method for the synthesis of the same and their employment for the preparation of pharmaceutical compositions
US5013723A (en)	1987-03-19	1991-05-07	Eniricerche S.P.A.	New thymopentin retro-inverso analogs and fragments thereof, a process of preparation of the new compounds and the intermediates obtained therein
US5021551A (en)	1989-01-18	1991-06-04	Washington University	Method of enhancing peptide immunogenicity

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3832337A (en) *	1970-07-28	1974-08-27	Squibb & Sons Inc	Peptide enzyme inhibitors
GB1526367A (en) *	1976-10-12	1978-09-27	Ici Ltd	Polypeptide
HU184481B (en) *	1981-10-02	1984-08-28	Richter Gedeon Vegyeszet	Process for producing tripeptides for diminishing appetite
JPS5921656A (ja) *	1982-07-28	1984-02-03	Takeda Chem Ind Ltd	ポリペプチド誘導体
SU1737798A1 (ru) *	1989-04-11	1995-03-20	Институт клинической иммунологии СО АМН СССР	Способ получения иммуностимулирующих тимусных полипептидов
IT1263042B (it) *	1993-01-15	1996-07-24	Enichem Polimeri	Composizione da stampaggio a base di polifenilenetere
AU7392294A (en) *	1993-07-21	1995-02-20	Vladimir Khatskelevich Khavinson	Pharmaceutical with immunomodulating activity

1995
- 1995-06-07 RU RU95108559A patent/RU2107692C1/ru active
1996
- 1996-05-06 EP EP96915261A patent/EP0832900B1/en not_active Expired - Lifetime
- 1996-05-06 ES ES96915261T patent/ES2217311T3/es not_active Expired - Lifetime
- 1996-05-06 UA UA98010039A patent/UA48974C2/uk unknown
- 1996-05-06 HU HU9801990A patent/HU228461B1/hu not_active IP Right Cessation
- 1996-05-06 SK SK1669-97A patent/SK281825B6/sk not_active IP Right Cessation
- 1996-05-06 CA CA002222296A patent/CA2222296C/en not_active Expired - Fee Related
- 1996-05-06 CN CNB961951532A patent/CN1154653C/zh not_active Expired - Fee Related
- 1996-05-06 JP JP50033197A patent/JP4082522B2/ja not_active Expired - Fee Related
- 1996-05-06 WO PCT/RU1996/000116 patent/WO1996040740A1/ru not_active Ceased
- 1996-05-06 BR BRPI9609235A patent/BRPI9609235B8/pt not_active IP Right Cessation
- 1996-05-06 DE DE69631762T patent/DE69631762T2/de not_active Expired - Lifetime
- 1996-05-06 CZ CZ19973905A patent/CZ287816B6/cs not_active IP Right Cessation
- 1996-05-06 DK DK96915261T patent/DK0832900T3/da active
- 1996-05-06 PT PT96915261T patent/PT832900E/pt unknown
- 1996-05-06 AU AU57076/96A patent/AU724781B2/en not_active Ceased
- 1996-05-06 AT AT96915261T patent/ATE260933T1/de active
- 1996-06-07 US US08/657,888 patent/US5736519A/en not_active Expired - Lifetime
1997
- 1997-12-19 LV LVP-97-266A patent/LV12074B/lv unknown
1998
- 1998-01-07 LT LT98-004A patent/LT4476B/lt not_active IP Right Cessation

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH659586A5 (de)	1985-07-02	1987-02-13	Le G Ped I	Arzneimittel aus dem thymus und verfahren zu dessen herstellung.
EP0230052A2 (en)	1985-12-26	1987-07-29	Arthur A. Gottlieb	Immunoamplifiers and related Compositions
US5013723A (en)	1987-03-19	1991-05-07	Eniricerche S.P.A.	New thymopentin retro-inverso analogs and fragments thereof, a process of preparation of the new compounds and the intermediates obtained therein
WO1989006134A1 (fr)	1987-12-30	1989-07-13	Vsesojuzny Kardiologichesky Nauchny Tsentr Akademi	Preparation pharmaceutique pour traiter des etats immunodeficitaires
US5021551A (en)	1989-01-18	1991-06-04	Washington University	Method of enhancing peptide immunogenicity
EP0406931A2 (en)	1989-06-30	1991-01-09	SCLAVO S.p.A.	New analogues of all-bond retroinverted thymopentin, the method for the synthesis of the same and their employment for the preparation of pharmaceutical compositions

Also Published As

Publication number	Publication date
AU724781B2 (en)	2000-09-28
LT98004A (en)	1998-10-26
CZ390597A3 (cs)	1998-08-12
CA2222296A1 (en)	1996-12-19
LV12074A (lv)	1998-06-20
ATE260933T1 (de)	2004-03-15
HUP9801990A3 (en)	1999-06-28
SK166997A3 (en)	1998-04-08
LV12074B (lv)	1998-08-20
JPH11513016A (ja)	1999-11-09
DE69631762D1 (de)	2004-04-08
EP0832900B1 (en)	2004-03-03
CN1189837A (zh)	1998-08-05
AU5707696A (en)	1996-12-30
CA2222296C (en)	2001-10-09
BRPI9609235B8 (pt)	2016-09-27
ES2217311T3 (es)	2004-11-01
HUP9801990A2 (hu)	1999-02-01
UA48974C2 (uk)	2002-09-16
SK281825B6 (sk)	2001-08-06
US5736519A (en)	1998-04-07
WO1996040740A1 (fr)	1996-12-19
DE69631762T2 (de)	2005-03-10
CZ287816B6 (en)	2001-02-14
DK0832900T3 (da)	2004-06-21
HK1014965A1 (en)	1999-10-08
PT832900E (pt)	2004-07-30
RU2107692C1 (ru)	1998-03-27
EP0832900A1 (en)	1998-04-01
CN1154653C (zh)	2004-06-23
BR9609235B1 (pt)	2009-01-13
JP4082522B2 (ja)	2008-04-30
HU228461B1 (en)	2013-03-28
EP0832900A4 (en)	1999-10-06
BR9609235A (pt)	1999-12-21

Legal Events

Date	Code	Title	Description
1999-06-25	PC9A	Transfer of patents	Free format text: IMMUNOTECH DEVELOPMENTS INC.,222 ISLINGTON AVENUE, TORONTO, ONTARIO, CANADA M8V 3W7,CA,990510
2015-12-28	MM9A	Lapsed patents	Effective date: 20150506

Publication	Publication Date	Title
JP4082522B2 (ja)	2008-04-30	ペプチドと、その製造方法
RU2107691C1 (ru)	1998-03-27	Пептид и способ его получения
US4472305A (en)	1984-09-18	Hexapeptide amides
EP0109418A1 (en)	1984-05-30	Gonadoliberin derivatives, process for the preparation and pharmaceutical and veterinary compositions thereof
DE69024230T2 (de)	1996-05-02	An fette gebundene aminosäuren, peptide oder deren derivate
RU2067000C1 (ru)	1996-09-27	Пептид и способ его получения
CS204011B2 (en)	1981-03-31	Process for preparing substituted pentapeptides
EP0253190A2 (en)	1988-01-20	Partially retro-inverted tuftsin analogues, method for the preparation thereof and pharmaceutical compositions containing them
US6034058A (en)	2000-03-07	Semi-synthetic alanyl dilemnin analogs
US5013723A (en)	1991-05-07	New thymopentin retro-inverso analogs and fragments thereof, a process of preparation of the new compounds and the intermediates obtained therein
US3472832A (en)	1969-10-14	Peptides related to caerulein
VARGA‐DEFTERDAROVIĆ et al.	1992	Glycoconjugates of opioid peptides: Synthesis and biological activity of [Leu5] enkephalin related glycoconjugates with amide type of linkage
US3757003A (en)	1973-09-04	Process for preparing l pyroglutamyl l histidyl l prolinamide
RU1124544C (ru)	1995-01-09	Гептапептид, обладающий свойствами психостимулятора пролонгированного действия с иммунотропной активность
US4111923A (en)	1978-09-05	Octapeptides and methods for their production
US4018754A (en)	1977-04-19	Novel polypeptides having ACTH-like action
KR0133850B1 (ko)	1998-04-21	Sdk 펩디드, 그의 제조 방법 및 그를 함유하는 치료 조성물
Matsuura et al.	1970	Studies of Peptide Antibiotics. XVI. Analogs of Gramicidin S Containing β-Alanine in Place of l-Proline
DE68913936T2 (de)	1994-07-07	Retro-Inverso-Thrymopentin-Analoge, Verfahren zu deren Herstellung und deren Verwendung für die Zubereitung von pharmazeutischen Zusammensetzungen.
Lee et al.	1977	CYCLIC PEPTIDES: II. Synthesis of a Cyclodepsipeptide, Protodestruxin
US4271152A (en)	1981-06-02	Psycho-pharmacological peptides
SU1116698A1 (ru)	1990-10-07	Аналоги энкефалина, обладающие анальгетической активностью
Dzierzbicka	2008	Synthesis of new conjugates of MDP and nor-MDP with retro-tuftsin derivatives as potential immunomodulators
CA1336738C (en)	1995-08-15	Intermediates produced during the preparation of new thymopentin retroinverso analogs
Husman	1976	THE SYNTHESIS OF PEPTIDES AND DEPSIPEPTIDES RELATED TO ESPERIN.